BioInvent International
BINV | ST
Overview
Corporate Details
- ISIN(s):
- SE0015244520
- LEI:
- 549300E7QRHEF2IJUY10
- Country:
- Sweden
- Address:
- C/O BioInvent International Aktiebolag, 223 70 Lund
- Website:
- https://www.bioinvent.com/en
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
BioInvent International AB is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase l/ll trials for the treatment of hematological cancer and solid tumors, respectively. The Company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company’s fully integrated manufacturing unit.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-12 09:00 |
Earnings Release
BioInvent presenterar lovande fas 2a-monoterapidata för BI-1808 i CTCL på EHA 2…
|
Swedish | 82.1 KB | |
| 2025-06-12 09:00 |
Regulatory News Service
BioInvent Presents Promising Phase 2a Monotherapy Data for BI-1808 in CTCL at E…
|
English | 82.1 KB | |
| 2025-05-27 14:00 |
M&A Activity
XOMA Royalty förvärvar mezagitamab royalty- och milstolpsrättigheter av BioInve…
|
Swedish | 89.3 KB | |
| 2025-05-27 14:00 |
M&A Activity
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInve…
|
English | 90.2 KB | |
| 2025-05-14 15:30 |
Regulatory News Service
BioInvent presenterar ytterligare fas 2a-data för BI-1808 monoterapi i CTCL på …
|
Swedish | 81.5 KB | |
| 2025-05-14 15:30 |
Regulatory News Service
BioInvent Announces Updated Phase 2a Triple Combination Arm Data of BI-1206, ri…
|
English | 81.8 KB | |
| 2025-05-14 15:30 |
Earnings Release
Uppdatering från BioInvents fas 2a-trippelkombinationsstudie med BI-1206, ritux…
|
Swedish | 81.9 KB | |
| 2025-05-14 15:30 |
Regulatory News Service
BioInvent Presents Additional CTCL Phase 2a Data for BI-1808 Monotherapy at EHA…
|
English | 80.8 KB | |
| 2025-04-29 17:01 |
Post-Annual General Meeting Information
Beslut på BioInvents årsstämma 2025
|
Swedish | 71.8 KB | |
| 2025-04-29 17:01 |
Post-Annual General Meeting Information
Resolutions at BioInvent’s Annual General Meeting 2025
|
English | 71.6 KB | |
| 2025-04-29 08:00 |
Earnings Release
|
Swedish | 3.8 MB | |
| 2025-04-29 08:00 |
Quarterly Report
|
English | 3.7 MB | |
| 2025-03-25 10:00 |
Pre-Annual General Meeting Information
Notice to Annual General Meeting in BioInvent International AB
|
English | 110.1 KB | |
| 2025-03-25 10:00 |
Pre-Annual General Meeting Information
Kallelse till årsstämma i BioInvent International AB
|
Swedish | 108.0 KB | |
| 2025-02-27 08:00 |
Annual / Quarterly Financial Statement
|
Swedish | 3.0 MB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-09 | Erik Esveld | Other | Buy | 4,000 | 70,960.00 SEK |
| 2023-06-30 | Sylvie Ryckebusch | Other | Buy | 5,000 | 7,890.00 EUR |
| 2022-11-16 | Dharminder Chahal | Other | Buy | 10,000 | 352,500.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 3,262 | 109,798.92 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 800 | 27,200.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 750 | 25,425.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 611 | 20,700.68 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 530 | 17,193.20 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 500 | 16,800.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 400 | 13,712.00 SEK |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
4SC AG | Germany | VSC | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC |